

# Asian-Pacific consensus statement on the management

Liver International

25, 472-489

DOI: [10.1111/j.1478-3231.2005.01134.x](https://doi.org/10.1111/j.1478-3231.2005.01134.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Therapeutic implications of hepatitis B virus genotypes. <i>Liver International</i> , 2005, 25, 1097-1107.	1.9	100
2	Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2005, 4, 13.	1.7	82
3	Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. <i>Gut</i> , 2005, 54, 1597-1603.	6.1	136
4	Current Treatment of Chronic Hepatitis B: Benefits and Limitations. <i>Seminars in Liver Disease</i> , 2005, 25, 20-28.	1.8	75
5	Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine. <i>New England Journal of Medicine</i> , 2005, 353, 1630-1631.	13.9	0
6	Clevudine for the treatment of chronic hepatitis B virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 1277-1284.	1.9	20
7	Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2005, 352, 2682-2695.	13.9	1,465
8	Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. <i>Journal of Hepatology</i> , 2005, 43, 72-77.	1.8	37
9	Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1835-1843.	0.9	27
10	Do We Still Need a Liver Biopsy? Are the Serum Fibrosis Tests Ready for Prime Time?. <i>Clinics in Liver Disease</i> , 2006, 10, 513-534.	1.0	22
11	Management of Drug-Resistant Chronic Hepatitis B. <i>Clinics in Liver Disease</i> , 2006, 10, 275-302.	1.0	11
12	Chronic Hepatitis B: Current Testing Strategies. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 666-676.	2.4	70
13	Chronic Hepatitis B: A Critical Appraisal of Current Approaches to Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 233-248.	2.4	43
14	Hepatitis B Virus Replication x Time Equals Trouble. <i>Gastroenterology</i> , 2006, 130, 989-991.	0.6	17
15	Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2006, 130, 2039-2049.	0.6	391
16	Entecavir. <i>Drugs</i> , 2006, 66, 1605-1622.	4.9	28
20	A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 936-962.	2.4	371
21	Early mortality in taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors. <i>Clinical Therapeutics</i> , 2006, 28, 2081-2092.	1.1	24

#	ARTICLE	IF	CITATIONS
22	Management of chronic hepatitis B: an evolving issue. <i>Liver International</i> , 2006, 26, 1-2.	1.9	4
23	Chronic hepatitis B: treatment alert. <i>Liver International</i> , 2006, 26, 47-58.	1.9	27
24	Management of chronic hepatitis B in challenging patient populations. <i>Liver International</i> , 2006, 26, 38-46.	1.9	9
25	Diagnosis and management of chronic hepatitis B in the primary care setting. <i>Postgraduate Medicine</i> , 2006, 119, 28-36.	0.9	3
26	Canadian Consensus on Medically Acceptable Wait Times for Digestive Health Care. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2006, 20, 411-423.	1.8	113
27	Pegylated Interferons for the Treatment of Chronic Hepatitis B. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2006, 1, 85-94.	0.5	4
28	The ways paved for prophylaxis against de novo hepatitis B virus infection after liver transplantation: still many stones left unturned. <i>Pediatric Transplantation</i> , 2006, 10, 405-407.	0.5	7
29	RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells. <i>Chinese Journal of Digestive Diseases</i> , 2006, 7, 230-236.	1.1	6
30	Non-invasive models for predicting histology in patients with chronic hepatitis B. <i>Liver International</i> , 2006, 26, 666-672.	1.9	115
31	Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. <i>Liver International</i> , 2006, 26, 796-804.	1.9	10
32	Management of chronic hepatitis B virus infection: Current perspectives for the nurse practitioner. <i>Journal of the American Academy of Nurse Practitioners</i> , 2006, 18, 203-215.	1.4	5
33	Reactivation of Hepatitis B Virus in Rheumatologic Patients Receiving Immunosuppressive Agents. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1627-1632.	1.1	24
35	Therapy of hepatitis B – Viral suppression or eradication?. <i>Hepatology</i> , 2006, 43, S182-S193.	3.6	57
36	Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. <i>Hepatology</i> , 2006, 43, 209-220.	3.6	474
37	Interferon $\alpha$ -2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study. <i>Hepatology</i> , 2006, 43, 742-749.	3.6	41
38	A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2006, 44, 108-116.	3.6	68
39	Recommendations and potential future options in the treatment of hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2225-2231.	0.9	0
40	Selecting Appropriate Management Strategies for Chronic Hepatitis B: Who to Treat. <i>American Journal of Gastroenterology</i> , 2006, 101, S7-S12.	0.2	27

#	ARTICLE	IF	CITATIONS
41	Advancing Patient Care: Integrating New Data. <i>American Journal of Gastroenterology</i> , 2006, 101, S32-S39.	0.2	7
42	Characterization of a New Sensitive PCR Assay for Quantification of Viral DNA Isolated from Patients with Hepatitis B Virus Infections. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3948-3953.	1.8	40
43	Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 201-205.	1.3	32
44	Accuracy of a referral guideline for patients with chronic hepatitis B in primary care to select patients eligible for evaluation by a specialist. <i>Gut</i> , 2007, 56, 1027-1028.	6.1	9
45	Screening for and Treating Hepatitis B Virus in Patients with HIV Infection. <i>Clinical Infectious Diseases</i> , 2007, 45, 633-636.	2.9	3
46	Emerging drugs for hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 199-217.	1.0	13
47	Optimal duration of therapy in HBV-related cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 2-6.	1.3	8
48	Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B. <i>Clinical Microbiology Reviews</i> , 2007, 20, 426-439.	5.7	128
49	Telbivudine: a new option for the treatment of chronic hepatitis B. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 751-761.	1.4	35
50	When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection?. <i>Annals of Internal Medicine</i> , 2007, 147, 62.	2.0	13
51	The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points. <i>Annals of Internal Medicine</i> , 2007, 147, 58.	2.0	163
52	Cost-effectiveness of peginterferon $\alpha$ -2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 631-638.	0.8	18
53	Correlation Between Hepatitis B Virus DNA Levels and Liver Histology. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 339-342.	1.1	1
54	Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. <i>Vaccine</i> , 2007, 25, 1771-1779.	1.7	65
55	Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2007, 357, 2576-2588.	13.9	735
56	Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2007, 46, 45-52.	1.8	306
57	Economics of chronic hepatitis B and hepatitis C. <i>Journal of Hepatology</i> , 2007, 47, 608-617.	1.8	22
58	Best practice in the treatment of chronic hepatitis B: A summary of the European Viral Hepatitis Educational Initiative (EVHEI). <i>Journal of Hepatology</i> , 2007, 47, 588-597.	1.8	50

#	ARTICLE	IF	CITATIONS
59	Appropriate use of interferon for treatment of chronic hepatitis B. <i>Hepatology Research</i> , 2007, 37, S47-S54.	1.8	20
60	Improving outcomes for patients with chronic hepatitis B. <i>Hepatology Research</i> , 2007, 37, S67-S78.	1.8	5
61	Management of HBV infection in Japan. <i>Hepatology Research</i> , 2007, 37, S79-S82.	1.8	11
62	Chronic hepatitis B. <i>Hepatology</i> , 2007, 45, 507-539.	3.6	2,422
63	Hepatitis B virus infection. <i>Seminars in Fetal and Neonatal Medicine</i> , 2007, 12, 160-167.	1.1	189
64	Entecavir: a guide to its use in chronic hepatitis B. <i>Drugs and Therapy Perspectives</i> , 2007, 23, 1-4.	0.3	0
65	Chronic Hepatitis B Virus Carriers in the Immunotolerant Phase of Infection: Histologic Findings and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 636-641.	2.4	118
66	Long-Term Outcomes in Hepatitis B: The REVEAL-HBV Study. <i>Clinics in Liver Disease</i> , 2007, 11, 797-816.	1.0	176
67	Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 890-897.	2.4	268
68	Viremia Profiles in Children With Chronic Hepatitis B Virus Infection and Spontaneous e Antigen Seroconversion. <i>Gastroenterology</i> , 2007, 132, 2340-2345.	0.6	72
69	Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2007, 133, 1437-1444.	0.6	324
70	Management of Chronic Hepatitis B: Consensus Guidelines. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 5C-24C.	1.8	65
71	Long-term Outcome after Prophylactic Lamivudine Treatment on Hepatitis B Virus Reactivation in Non-Hodgkin's Lymphoma. <i>Yonsei Medical Journal</i> , 2007, 48, 78.	0.9	17
72	Novel approaches towards conquering hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2007, 13, 830.	1.4	17
74	Guideline on prevention and treatment of chronic hepatitis B in China (2005). <i>Chinese Medical Journal</i> , 2007, 120, 2159-2173.	0.9	89
75	Rescue therapy for lamivudine-resistant chronic hepatitis B: When and how?. <i>Hepatology</i> , 2007, 45, 266-268.	3.6	26
76	Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. <i>Hepatology</i> , 2007, 46, 1041-1048.	3.6	112
77	Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Journal of Medical Virology</i> , 2007, 79, 663-669.	2.5	6

#	ARTICLE	IF	CITATIONS
78	Liver injury is associated with enhanced regulatory T-cell activity in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2007, 14, 503-511.	1.0	23
79	The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. <i>Journal of Viral Hepatitis</i> , 2007, 14, 751-766.	1.0	18
80	Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 377-382.	1.9	34
81	Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients. <i>Liver International</i> , 2007, 27, 235-239.	1.9	7
82	Defining Optimal Therapeutic Outcomes in Chronic Hepatitis. <i>Archives of Medical Research</i> , 2007, 38, 652-660.	1.5	4
83	Adverse effects of high-dose interferon- $\alpha$ 2a treatment for chronic hepatitis B. <i>Advances in Therapy</i> , 2007, 24, 963-971.	1.3	18
84	Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma. <i>Current Hepatitis Reports</i> , 2007, 6, 9-16.	0.3	13
85	Hepatitis B virus genotype: What should the clinician know?. <i>Current Hepatitis Reports</i> , 2007, 6, 17-23.	0.3	7
86	A Case of Hyperthyroidy Developing in Pegylated-Interferon Therapy. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1194-1196.	1.1	4
87	Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state". <i>Hepatology International</i> , 2007, 1, 281-284.	1.9	18
88	Towards a rational treatment strategy for chronic hepatitis B. <i>Hepatology International</i> , 2007, 1, 285-286.	1.9	1
89	Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. <i>Hepatology International</i> , 2007, 1, 316-325.	1.9	20
90	Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. <i>Hepatology International</i> , 2007, 1, 365-372.	1.9	42
91	Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. <i>Hepatology International</i> , 2007, 1, 373-381.	1.9	13
92	Role of viral factors in the natural course and therapy of chronic hepatitis B. <i>Hepatology International</i> , 2007, 1, 415-430.	1.9	84
93	Assessing routine and serum markers of liver fibrosis in CHB patients using parallel and serial interpretation. <i>Clinical Biochemistry</i> , 2007, 40, 562-566.	0.8	21
94	Sustained response to peginterferon alfa-2a (40kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. <i>Hepatology International</i> , 2008, 2, 102-110.	1.9	76
96	Natural history and clinical management of chronic hepatitis B virus infection in children. <i>Hepatology International</i> , 2008, 2, 28-36.	1.9	47

#	ARTICLE	IF	CITATIONS
97	New developments in HBV molecular diagnostics and quantitative serology. <i>Hepatology International</i> , 2008, 2, 3-11.	1.9	19
98	Hepatitis B reactivation after chemotherapy: two decades of clinical research. <i>Hepatology International</i> , 2008, 2, 152-162.	1.9	103
99	Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. <i>Hepatology International</i> , 2008, 2, 19-27.	1.9	8
100	Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. <i>Hepatology International</i> , 2008, 2, 163-178.	1.9	50
101	Chronic HBV infection with persistently normal ALT b. not to treat. <i>Hepatology International</i> , 2008, 2, 185-189.	1.9	18
102	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. <i>Hepatology International</i> , 2008, 2, 263-283.	1.9	832
103	Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. <i>Journal of Medical Virology</i> , 2008, 80, 1160-1170.	2.5	44
105	Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. <i>Hepatology</i> , 2008, 48, 99-108.	3.6	173
106	A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 794-803.	1.4	27
107	Economic evaluation of chronic hepatitis B treatments in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 571-579.	1.4	14
108	Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 512-520.	1.4	181
109	New paradigms for the treatment of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1182-1192.	1.4	23
110	Antiviral therapy for various stages of HBV-related diseases: Lamivudine and beyond. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 681-682.	1.4	0
111	Natural history of chronic hepatitis B virus infection: What determines prognosis after cirrhotic decompensation?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1631-1632.	1.4	5
113	Management of hepatitis virus infections. <i>Haemophilia</i> , 2008, 14, 26-32.	1.0	1
114	High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. <i>Journal of Viral Hepatitis</i> , 2008, 15, 615-621.	1.0	74
115	Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. <i>Journal of Viral Hepatitis</i> , 2008, 15, 753-760.	1.0	42
116	Elevated Perioperative Transaminase Level Predicts Intrahepatic Recurrence in Hepatitis B-related Hepatocellular Carcinoma After Curative Hepatectomy. <i>Asian Journal of Surgery</i> , 2008, 31, 41-49.	0.2	39

#	ARTICLE	IF	CITATIONS
119	Approach to patients with HBV and HCV coinfection. <i>Current Hepatitis Reports</i> , 2008, 7, 18-24.	0.3	0
120	Virologic and Histologic Features of Chronic Hepatitis B Virus-Infected Asymptomatic Patients With Persistently Normal ALT. <i>Gastroenterology</i> , 2008, 134, 1376-1384.	0.6	349
121	Need to Strictly Define Hepatitis B Virus Immunotolerant Patients to Avoid Unnecessary Liver Biopsy. <i>Gastroenterology</i> , 2008, 135, 2155-2156.	0.6	7
122	Drugs Treatment of Hepatitis B. <i>Farmacia Hospitalaria (English Edition)</i> , 2008, 32, 234-248.	0.0	0
123	Treatment of chronic hepatitis B: Recommendations from an Italian workshop. <i>Digestive and Liver Disease</i> , 2008, 40, 603-617.	0.4	50
124	Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naïve chronic hepatitis B patients. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 569-579.	2.0	18
125	Viral Hepatitis in Elderly Haemodialysis Patients. <i>Drugs and Aging</i> , 2008, 25, 823-840.	1.3	9
127	96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. <i>Journal of Hepatology</i> , 2008, 48, 714-720.	1.8	63
128	Hepatitis B: Reflections on the current approach to antiviral therapy. <i>Journal of Hepatology</i> , 2008, 48, S2-S19.	1.8	142
129	Combination therapy for chronic hepatitis B: Ready for prime time?. <i>Journal of Hepatology</i> , 2008, 48, 687-691.	1.8	7
130	Treatment predictors of a sustained virologic response in hepatitis B and C. <i>Journal of Hepatology</i> , 2008, 49, 634-651.	1.8	290
131	Chronic hepatitis B in 2008. <i>Digestive and Liver Disease Supplements</i> , 2008, 2, 3-6.	0.2	1
132	Tratamiento de las hepatitis virales. <i>EMC - Tratado De Medicina</i> , 2008, 12, 1-11.	0.0	0
133	Hepatitis B Virus Infection. <i>New England Journal of Medicine</i> , 2008, 359, 1486-1500.	13.9	830
135	Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 167-178.	4.6	182
136	A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1315-1341.	2.4	450
137	Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1027-1035.	2.4	143
138	Telbivudine: a hepatitis B-specific antiviral. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 217-229.	1.3	0



#	ARTICLE	IF	CITATIONS
139	Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. <i>Applied Health Economics and Health Policy</i> , 2008, 6, 231-246.	1.0	12
140	Diagnosis of hepatitis B virus infection through serological and virological markers. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 553-562.	1.4	117
141	Molecular Genetic Diversity of Hepatitis B Virus in Kenya. <i>Intervirology</i> , 2008, 51, 417-421.	1.2	22
142	Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2008, 103, 3071-3081.	0.2	83
143	Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 2776-2783.	0.2	114
144	Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. <i>Carcinogenesis</i> , 2008, 29, 106-112.	1.3	81
145	CD4 <sup>+</sup> CD25 <sup>+</sup> regulatory T cells: a therapeutic target for liver diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 313-326.	1.5	6
147	Changes in Liver Histology as a "Surrogate" End Point of Antiviral Therapy for Chronic HBV Can Predict Progression to Liver Complications. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 533-538.	1.1	6
148	The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 797-802.	0.9	5
149	Chronic hepatitis B and C infection in children in New South Wales. <i>Medical Journal of Australia</i> , 2009, 190, 670-673.	0.8	11
150	DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. <i>World Journal of Gastroenterology</i> , 2009, 15, 423.	1.4	31
151	Current Challenges in Hepatitis C. <i>TAJ Journal of Teachers Association</i> , 2009, 21, 93-96.	0.1	2
152	Evaluation of Liver Biopsy in Egyptian HBeAg-Negative Chronic Hepatitis B Patients at Initial Presentation: Implications for Therapy. <i>American Journal of Gastroenterology</i> , 2009, 104, 906-911.	0.2	24
153	Randomized Controlled Study Investigating Viral Suppression and Serological Response following Pre-S1/Pre-S2/S Vaccine Therapy Combined with Lamivudine Treatment in HBeAg-Positive Patients with Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 5134-5140.	1.4	49
154	Prevention of hepatitis B virus reactivation under rituximab therapy. <i>Immunotherapy</i> , 2009, 1, 1053-1061.	1.0	14
155	From lab to bedside: emerging clinical applications of thymosin $\alpha 1$ . <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 593-608.	1.4	84
156	HBV and HCV Therapy. <i>Viruses</i> , 2009, 1, 484-509.	1.5	7
157	Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA > 2000 IU/mL. <i>Hepatology</i> , 2009, 49, 704-705.	3.6	5

#	ARTICLE	IF	CITATIONS
158	Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. <i>Hepatology</i> , 2009, 49, S35-S44.	3.6	237
159	Antiviral resistance and hepatitis B therapy. <i>Hepatology</i> , 2009, 49, S174-S184.	3.6	189
160	Benefits and risks of combination therapy for hepatitis B. <i>Hepatology</i> , 2009, 49, S122-S128.	3.6	47
161	Reactivation of hepatitis B. <i>Hepatology</i> , 2009, 49, S156-S165.	3.6	486
162	Special populations with hepatitis B virus infection. <i>Hepatology</i> , 2009, 49, S146-S155.	3.6	40
163	Durability of Antiviral Response in HBeAg-Positive Chronic Hepatitis B Patients Who Maintained Virologic Response for One Year After Lamivudine Discontinuation. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1572-1577.	1.1	10
164	Society guidelines, US treatment algorithm, and NIH consensus: Similarities and differences in management of hepatitis B. <i>Current Hepatitis Reports</i> , 2009, 8, 161-168.	0.3	0
165	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009, 16, 36-44.	1.0	363
166	Long-term RNA interference and its application to hepatitis B virus. <i>Journal of Digestive Diseases</i> , 2009, 10, 165-171.	0.7	5
167	Pretreatment alanine transaminase level may not be the most important predictor of HBeAg loss in the older patient. <i>Liver International</i> , 2009, 29, 231-236.	1.9	4
168	Treatment of HBeAg-positive patients with nucleos/tide analogues. <i>Liver International</i> , 2009, 29, 116-124.	1.9	5
169	HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon. <i>Liver International</i> , 2009, 29, 125-129.	1.9	6
170	Identifying hepatitis C virus: endemic areas and estimating the viral antibody prevalence based on the prevalence of ALT elevation. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2009, 103, 917-923.	0.7	3
171	Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. <i>Journal of Clinical Virology</i> , 2009, 45, 114-118.	1.6	43
172	What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? Beyond the applause for higher sensitivity. <i>Journal of Hepatology</i> , 2009, 50, 212.	1.8	0
173	Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy. <i>Journal of Hepatology</i> , 2009, 50, 289-295.	1.8	96
174	Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. <i>Journal of Hepatology</i> , 2009, 50, 990-998.	1.8	46
175	Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2009, 51, 640-646.	1.8	76

#	ARTICLE	IF	CITATIONS
176	Entecavir. <i>Drugs</i> , 2009, 69, 1003-1033.	4.9	38
177	Interferons and Their Use in Persistent Viral Infections. <i>Handbook of Experimental Pharmacology</i> , 2009, , 203-241.	0.9	19
178	Management of patients co-infected with HBV and HCV. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 549-558.	2.0	4
179	Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. <i>Journal of Clinical Oncology</i> , 2009, 27, 605-611.	0.8	576
180	Pathobiology of HBV mutants and clinical impact for treatment monitoring. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 309-320.	2.0	17
181	A Significant Proportion of Patients With Chronic Hepatitis B Who are Candidates for Antiviral Treatment are Untreated. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 1001-1007.	1.1	22
182	Treatment of Chronic Hepatitis B in Asia-Pacific Countries: Is the Asia-Pacific Consensus Statement being followed?. <i>Antiviral Therapy</i> , 2010, 15, 607-616.	0.6	10
183	Baseline and On-Treatment Predictors for Outcome of Chronic Hepatitis B Treatment. <i>Current Hepatitis Reports</i> , 2010, 9, 53-59.	0.3	1
184	Update on Chronic Hepatitis B. <i>Journal for Nurse Practitioners</i> , 2010, 6, 631-639.	0.4	1
185	Genotype X/C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam—genotypes B4 and C1 predominate. <i>Journal of Medical Virology</i> , 2010, 82, 1327-1333.	2.5	41
186	Identification of the risk for liver fibrosis on CHB patients using an artificial neural network based on routine and serum markers. <i>BMC Infectious Diseases</i> , 2010, 10, 251.	1.3	35
187	Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. <i>BMC Health Services Research</i> , 2010, 10, 215.	0.9	9
188	Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2010, 17, 298-304.	1.0	42
189	Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 657-663.	1.4	134
190	Rescue therapy for lamivudine-resistant chronic hepatitis B: Comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1374-1380.	1.4	58
191	Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study. <i>Journal of Korean Medical Science</i> , 2010, 25, 882.	1.1	15
192	How to Overcome Antiviral-Resistant Hepatitis B Virus?. <i>Intervirology</i> , 2010, 53, 29-38.	1.2	4
193	Liver biopsy for histological assessment - the case against. <i>Saudi Journal of Gastroenterology</i> , 2010, 16, 124.	0.5	68

#	ARTICLE	IF	CITATIONS
194	Rituximab Administration and Reactivation of HBV. <i>Hepatitis Research and Treatment</i> , 2010, 2010, 1-8.	2.0	21
195	Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Oncology</i> , 2010, 28, 2437-2444.	0.8	249
196	End points of therapy in chronic hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 37-49.	1.4	3
197	Hepatitis B Virus Load in Serum Does Not Reflect Histologic Activity in Patients With Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 60-65.	2.4	9
198	End-points in hepatitis B treatment. <i>Arab Journal of Gastroenterology</i> , 2010, 10, S23-S24.	0.4	0
199	Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 75-81.	0.6	36
200	Medical Management of Chronic Liver Diseases in Children (Part I). <i>Paediatric Drugs</i> , 2011, 13, 357-370.	1.3	12
201	Antiviral drugs for HBV liver disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 285-300.	1.4	21
203	Pyogenic Liver Abscess as the Initial Manifestation of Underlying Hepatocellular Carcinoma. <i>American Journal of Medicine</i> , 2011, 124, 1158-1164.	0.6	59
204	HBV DNA Loss within 24 Weeks Predicts Late Viral Breakthrough in Chronic Hepatitis B. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2011, 58, 25.	0.2	0
205	Risk of HBV Reactivation According to Viral Status and Treatment Intensity in Patients with Hepatocellular Carcinoma. <i>Antiviral Therapy</i> , 2011, 16, 969-977.	0.6	62
206	Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective study. <i>Virology Journal</i> , 2011, 8, 444.	1.4	7
207	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study. <i>Antiviral Research</i> , 2011, 92, 90-95.	1.9	22
208	A336C/A336T/T337C variations in HBV core gene and spontaneous hepatitis B e antigen loss in chronic hepatitis B patients. <i>Virology Journal</i> , 2011, 8, 226.	1.4	2
209	High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. <i>Journal of Medical Virology</i> , 2011, 83, 968-973.	2.5	41
210	The ethics of placebo treatment for patients with acute exacerbation of chronic hepatitis B. <i>Hepatology</i> , 2011, 54, 740-740.	3.6	0
211	Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. <i>Carcinogenesis</i> , 2011, 32, 876-881.	1.3	53
212	Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1719-1725.	0.5	159

#	ARTICLE	IF	CITATIONS
213	The Liver in Pregnancy. , 2012, , 919-940.		3
214	High Frequency of Recurrent Viremia After Hepatitis B e Antigen Seroconversion and Consolidation Therapy. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 865-870.	1.1	63
215	A survey on the current trends in the management of hepatitis B in China. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 884-889.	0.8	8
216	Foxp3 <sup>+</sup> regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 644-655.	1.9	37
218	The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up. <i>Hepatology International</i> , 2012, 6, 449-456.	1.9	4
219	Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. <i>The Cochrane Library</i> , 2013, , CD009004.	1.5	16
220	Comparison of the Efficacy of Lamivudine Plus Adefovir Versus Entecavir in the Treatment of Lamivudine-Resistant Chronic Hepatitis B: A Systematic Review and Meta-Analysis. <i>Clinical Therapeutics</i> , 2013, 35, 1997-2006.	1.1	17
221	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. <i>Hepatology</i> , 2013, 58, 1537-1547.	3.6	408
222	Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?. <i>Liver International</i> , 2013, 33, 157-163.	1.9	17
223	PegIFN- $\alpha$ 2a for the treatment of chronic hepatitis B and C: a 10-year history. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 459-474.	2.0	15
224	Hepatocellular Carcinoma: High Hepatitis B Viral Load and Mortality in Patients Treated with Transarterial Chemoembolization. <i>Radiology</i> , 2013, 267, 638-647.	3.6	28
225	Hepatitis B virus reactivation with rituximab-containing regimen. <i>World Journal of Hepatology</i> , 2013, 5, 612.	0.8	27
226	Liver diseases in pregnancy: Diseases unique to pregnancy. <i>World Journal of Gastroenterology</i> , 2013, 19, 7639.	1.4	70
227	Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 959-967.	1.0	2
228	Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: A head-to-head study. <i>Saudi Journal of Gastroenterology</i> , 2014, 20, 350.	0.5	6
229	Impact of Liver Biopsy on the Decision to Treat Patients with Chronic Hepatitis B Genotype D Virus Infection. <i>Intervirology</i> , 2014, 57, 248-253.	1.2	1
230	Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. <i>Hepatology International</i> , 2014, 8, 72-82.	1.9	11
231	Viral Hepatitis B: Clinical and Epidemiological Characteristics. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a024935-a024935.	2.9	74

#	ARTICLE	IF	CITATIONS
232	Hepatitis B Surface Antigen Seroclearance: Relationship to Hepatitis B e-Antigen Seroclearance and Hepatitis B e-Antigen-Negative Hepatitis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1764-1770.	0.2	19
233	Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine. <i>Vaccine</i> , 2014, 32, 6091-6097.	1.7	46
234	Hepatitis B virus reactivation with a rituximab-containing regimen. <i>World Journal of Hepatology</i> , 2015, 7, 2344.	0.8	63
235	Towards the elimination and eradication of hepatitis B. <i>Journal of Virus Eradication</i> , 2015, 1, 4-12.	0.3	7
236	Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. <i>Hepatology Research</i> , 2015, 45, 1220-1227.	1.8	14
237	Clinical course of chronic hepatitis B (<scp>CHB</scp>) presented with normal <scp>ALT</scp> in Asian American patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 809-816.	1.0	9
238	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. <i>Liver International</i> , 2015, 35, 2246-2255.	1.9	66
239	Hepatitis <scp>B</scp> reactivation during cancer chemotherapy: an international survey of the membership of the <scp>A</scp>merican Association for the Study of Liver Diseases. <i>Journal of Viral Hepatitis</i> , 2015, 22, 346-352.	1.0	46
240	ADVANCED LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS B AND VIRAL LOAD BELOW 2,000 IU/mL. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2016, 58, 65.	0.5	5
241	The effect of small intestinal bacterial overgrowth on minimal hepatic encephalopathy in patients with cirrhosis. <i>Archives of Medical Science</i> , 2016, 3, 592-596.	0.4	20
242	Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 2293-2299.	0.8	4
244	Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 590-596.	0.7	2
245	Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/Tim-3 interaction. <i>Scientific Reports</i> , 2017, 7, 15280.	1.6	16
246	Distribution of peripheral dendritic cells in patients with HBV infection or spleen and kidney deficiency. <i>Journal of Medical Virology</i> , 2018, 90, 706-711.	2.5	0
248	Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. <i>Hepatology International</i> , 2019, 13, 665-673.	1.9	54
249	Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis. <i>World Journal of Surgical Oncology</i> , 2019, 17, 45.	0.8	9
250	Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection. <i>Clinical Infectious Diseases</i> , 2019, 70, 660-666.	2.9	16
251	The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection. <i>Medicine (United States)</i> , 2019, 98, e14386.	0.4	4

#	ARTICLE	IF	CITATIONS
252	The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of HBV-Related HCC After Curative Resection. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1419-1429.	0.9	5
253	Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 243-251.	1.4	4
254	Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 584-592.	1.8	51
255	Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135 395 patients from 2000 to 2017. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3487-3499.	1.4	8
256	The Liver in Pregnancy. , 2018, , 817-836.e5.		1
257	Chronic Viral Hepatitis. , 2010, , 1593-1617.		9
259	Relapse Rate and Associated-Factor of Recurrence after Stopping NUCs Therapy with Different Prolonged Consolidation Therapy in HBeAg Positive CHB Patients. <i>PLoS ONE</i> , 2013, 8, e68568.	1.1	22
261	Comparison of real-time polymerase chain reaction with the COBAS Amplicor test for quantitation of hepatitis B virus DNA in serum samples. <i>World Journal of Gastroenterology</i> , 2008, 14, 479.	1.4	8
262	Current treatment indications and strategies in chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2008, 14, 6902.	1.4	30
263	Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: A randomized controlled study. <i>World Journal of Gastroenterology</i> , 2006, 12, 6715.	1.4	45
264	Telbivudine: A new treatment for chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2007, 13, 6150.	1.4	30
265	Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: A case report. <i>World Journal of Gastroenterology</i> , 2007, 13, 964.	1.4	4
266	A prophylactic approach for bone marrow transplantation from a hepatitis B surface antigen-positive donor. <i>World Journal of Gastroenterology</i> , 2007, 13, 1138.	1.4	7
267	Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. <i>World Journal of Gastroenterology</i> , 2012, 18, 6106.	1.4	10
268	Liver diseases in pregnancy: Diseases not unique to pregnancy. <i>World Journal of Gastroenterology</i> , 2013, 19, 7630.	1.4	17
269	What physicians should know about the management of chronic hepatitis B in children: East side story. <i>World Journal of Gastroenterology</i> , 2014, 20, 3582.	1.4	11
270	Hepatitis B Reactivation During Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution's Experience. <i>Korean Journal of Internal Medicine</i> , 2007, 22, 237.	0.7	40
271	Management of Patients with Hepatitis B Virus Infection Who Receive Immunosuppressive Treatment or Chemotherapy. <i>Korean Journal of Medicine</i> , 2012, 82, 149.	0.1	3



#	ARTICLE	IF	CITATIONS
272	Knowledge of hepatitis B among healthy population: A community-based survey from two districts of Gujarat, India. <i>Journal of Family Medicine and Primary Care</i> , 2017, 6, 589.	0.3	10
273	Hepatic Failure Caused by Reactivation of YMDD Mutants Occurring during Preemptive Lamivudine Therapy. <i>Gut and Liver</i> , 2010, 4, 262-265.	1.4	6
274	Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. <i>Microorganisms</i> , 2021, 9, 2083.	1.6	16
275	Selecting Appropriate Management Strategies for Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2006, 101, S7-S12.	0.2	3
276	Advancing Patient Care. <i>American Journal of Gastroenterology</i> , 2006, 101, S32-S39.	0.2	0
277	New antiviral choice for chronic hepatitis B: tenofovir disoproxil fumarate. <i>World Chinese Journal of Digestology</i> , 2008, 16, 2679.	0.0	0
278	Importance of antiviral therapy for chronic hepatitis B. <i>World Chinese Journal of Digestology</i> , 2008, 16, 5.	0.0	0
281	Update on Chronic Hepatitis B (CHB) Treatment. <i>North American Journal of Medicine &amp; Science</i> , 2009, 2, 84.	3.8	0
282	Hepatitis B and D. , 2010, , 1287-1312.e5.		7
283	Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance. <i>World Journal of Gastroenterology</i> , 2010, 16, 4691.	1.4	0
284	Clinical Activity of SAAAB and HAABS Dietary Supplement on Hepatitis C and B Markers. <i>IOSR Journal of Pharmacy and Biological Sciences</i> , 2013, 5, 32-37.	0.1	0
285	Adefovir Dipivoxil, Tenofovir Disoproxil Fumarate or Lamivudine; Which is Suitable Monotherapy Medication in the Patients with Chronic Hepatitis B Virus Infection? One Year Experience. <i>Journal of Microbiology &amp; Experimentation</i> , 2014, 1, .	0.1	0
286	Hepatic Histologic Changes in Patients with Chronic Hepatitis B Virus Infection with High DNA Level and Normal or Minimally Elevated Alanine Aminotransferase. <i>Faridpur Medical College Journal</i> , 2016, 10, 3-8.	0.0	0
287	HEPATITISâ€“B VIRUS INFECTION;. <i>The Professional Medical Journal</i> , 2018, 21, 950-955.	0.0	0
288	Application and Reliability of Caprini Thrombus Risk Assessment Scale in Risk Assessment of Venous Thromboembolism in Acute and Severe Uygur Patients. <i>International Journal of Clinical Medicine</i> , 2019, 10, 596-603.	0.1	0
289	Hepatitis B Reactivation in Patients with Hematological and Solid Malignancies: A Retrospective Analysis of Single Centerâ€™s Experience. <i>International Journal of Clinical Medicine</i> , 2019, 10, 622-629.	0.1	0
290	Seroprevalence, Biochemical Investigation and Risk Factor Assessment for HBV & HCV Infection in Hospital Based Patients of Islamabad, Pakistan. <i>Journal of Bioresource Management</i> , 2020, 7, 10-18.	0.4	1
291	Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 605-12.	0.9	6



#	ARTICLE	IF	CITATIONS
292	Management of chronic hepatitis B: consensus guidelines. Canadian Journal of Gastroenterology & Hepatology, 2007, 21 Suppl C, 5C-24C.	1.8	37
293	Interpreting hepatitis B serology. Malaysian Family Physician, 2007, 2, 31-2.	0.2	0
294	Hepatitis B Infection: What The Primary Care Doctors Should Know. Malaysian Family Physician, 2006, 1, 8-10.	0.2	0
295	Towards the elimination and eradication of hepatitis B. Journal of Virus Eradication, 2015, 1, 4-12.	0.3	5
297	The Epidemiology, Natural History and Prevention of Hepatitis B: Implications of HIV Coinfection. Antiviral Therapy, 2007, 12, 3-13.	0.6	51
298	Major Causes of Antiviral drug Resistance and Implications for Treatment of Hepatitis B virus Monoinfection and Coinfection with HIV. Antiviral Therapy, 2007, 12, 15-23.	0.6	71
299	Treatment of Chronic Hepatitis B. Antiviral Therapy, 2007, 12, 33-41.	0.6	17
300	Virological Response to Different Combination Regimes of Peginterferon $\alpha$ -2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B. Antiviral Therapy, 2007, 12, 815-823.	0.6	28
301	Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon $\alpha$ -2a (40 kDa; PEGASYS®). Antiviral Therapy, 2008, 13, 555-562.	0.6	12
302	Genetic Variability of Hepatitis B virus and Response to Antiviral Therapy. Antiviral Therapy, 2008, 13, 613-624.	0.6	37
303	Novel Approaches to New Therapies for Hepatitis B Virus Infection. Antiviral Therapy, 2006, 11, 1-15.	0.6	23
304	Hepatitis B Virus Replication and Liver Disease Progression: The Impact of Antiviral Therapy. Antiviral Therapy, 2006, 11, 669-680.	0.6	109
305	Viral hepatitis: A narrative review of hepatitis A-E. World Journal of Meta-analysis, 2022, 10, 99-121.	0.1	0
306	DL-3-n-butylphthalide alleviates motor disturbance by suppressing ferroptosis in a rat model of Parkinson's disease. Neural Regeneration Research, 2023, 18, 194.	1.6	16
307	Expression changes of Tim-3 as one of supplementary indicators for monitoring prognosis of liver pathological changes in chronic HBV infection. BMC Infectious Diseases, 2022, 22, .	1.3	0
308	Knowledge of hepatitis B among healthy population in community. Arhivi Na Javnoto Zdravje, 2022, 14, .	0.1	0
309	Bacteremia (Sepsis), Hepatorenal Syndrome, and Serum Creatinine Levels Rather than Types or Microbial Patterns Predicted the Short-Term Survival of Cirrhotic Patients Complicated with Spontaneous Bacterial Peritonitis. Diagnostics, 2023, 13, 94.	1.3	1
310	Public Misperceptions About Transmission of Hepatitis B Virus in Singapore. Annals of the Academy of Medicine, Singapore, 2007, 36, 797-800.	0.2	11

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------